Scientists develop blood test that spots tumor-derived DNA in people with early stage cancers

https://hub.jhu.edu/2017/08/16/cancer-tumor-dna-blood-test/?utm_source=Hub+subscribers&utm_campaign=7a294dde15-EMAIL_CAMPAIGN_2017_08_17&utm_medium=email&utm_term=0_d8bf41c16e-7a294dde15-63587717

 

Promising screening test could cut down on over-testing for populations most at risk for certain cancers.

In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to accurately identify more than half of 138 people with relatively early stage colorectal, breast, lung, and ovarian cancers.

The test, the scientists say, is novel in that it can distinguish between DNA shed from tumors and other altered DNA that can be mistaken for cancer biomarkers.

OVERALL, THE SCIENTISTS WERE ABLE TO DETECT 62 PERCENT OF STAGE I AND II CANCERS.

A report on the research, performed on blood and tumor tissue samples from 200 people with all stages of cancer in the United States, Denmark, and the Netherlands, appears today in the journal Science Translational Medicine.

“This study shows that identifying cancer early using DNA changes in the blood is feasible and that our high accuracy sequencing method is a promising approach to achieve this goal,” says Victor Velculescu, professor of oncology at the Kimmel Cancer Center.

Blood tests for cancer are a growing part of clinical oncology, but they remain in the early stages of development. To find small bits of cancer-derived DNA in the blood of cancer patients, scientists have frequently relied on DNA alterations found in patients’ biopsied tumor samples as guideposts for the genetic mistakes they should be looking for among the masses of DNA circulating in those patients’ blood samples. To develop a cancer screening test that could be used to screen seemingly healthy people, scientists had to find novel ways to spot DNA alterations that could be lurking in a person’s blood but had not been previously identified.

“The challenge was to develop a blood test that could predict the probable presence of cancer without knowing the genetic mutations present in a person’s tumor,” says Velculescu.

The goal, adds Jillian Phallen, a graduate student at the Johns Hopkins Kimmel Cancer Center who was involved in the research, was to develop a screening test that is highly specific for cancer and accurate enough to detect the cancer when present, while reducing the risk of “false positive” results that often lead to unnecessary over-testing and over-treatment.

To develop the new test, Velculescu, Phallen and their colleagues obtained blood samples from 200 patients with breast, lung, ovarian, and colorectal cancer. The scientists’ blood test screened the patients’ blood samples for mutations within 58 genes widely linked to various cancers.

Among 42 people with colorectal cancer, the test correctly predicted cancer in 50 percent of patients with stage I, 89 percent of patients with stage II, 90 percent of patients with stage III, and 93 percent of patients with stage IV disease. For patients with lung cancer, the test correctly identified cancer among 45 percent of patients with stage I disease, 72 percent with stage II disease, 75 percent with stage III, and 83 percent with stage IV cancer. For 42 patients with ovarian cancer, the test identified 67 percent with stage I, 75 percent with stage II, 75 percent with stage III, and 83 percent with stage IV disease. Among 45 breast cancer patients, the test spotted cancer-derived mutations in 67 percent of patients with stage I disease, 59 percent with stage II, and 46 percent with stage III cancers.

Overall, the scientists were able to detect 86 of 138—62 percent—stage I and II cancers, and found none of the cancer-derived mutations among blood samples of 44 healthy individuals.

Despite these initial promising results for early detection, the blood test needs to be validated in studies of much larger numbers of people, say the scientists.

Velculescu and his team also performed independent genomic sequencing on available tumors removed from 100 of the 200 patients with cancer and found that 82 percent had mutations in their tumors that correlated with the genetic alterations found in the blood.

He says the populations that could benefit most from such a DNA-based blood test include those at high risk for cancer, including smokers, for whom standard computed tomography scans for identifying lung cancer often lead to false positives, and women with hereditary mutations for breast and ovarian cancer within BRCA1 and BRCA2 genes.

Northside Hospital and Gwinnett Health System agree to merge

https://www.bizjournals.com/atlanta/news/2017/08/17/northside-hospital-and-gwinnett-health-system.html

Image result for northside hospitalRelated image

 

After two years of negotiations, Northside Hospital and Gwinnett Health System, the parent of Gwinnett Medical Center, have agreed to merge.

The health systems submitted a merger agreement to the State of Georgia Office of the Attorney General, and if the plan is approved, the combined health system could be operational by early 2018.

Northside and Gwinnett first entered negotiations to merge in September 2015.

“Both systems have taken the necessary time to conduct this process carefully and deliberately,” the health systems said in a release.

It will take two years to fully integrate the two systems.The new system’s name and branding have not been determined yet.

“Northside Hospital is a leader in cancer care, women’s health and specialized surgical care, while Gwinnett Health System has strengths in cardiovascular care, sports medicine and post-acute care,” the systems said on a website launched Aug. 17 to help educate the public about the merger. “The service areas are adjacent to one another — ideal for focusing investment on care expansion, overall clinical capacity and improved patient access.”

No employees from either health system will lose their jobs as a result of the merger.

The Northside-Gwinnett combined system will have 1,479 beds, nearly 21,000 employees and 3,500 physicians.

Northside Hospital has hospitals in Sandy Springs, Cherokee County and Forsyth County. Gwinnett has hospitals in Duluth and Lawrenceville, Ga

UPMC bonds would fund major health care spending in midstate

http://www.pennlive.com/news/2017/08/upmc_bonds_would_fund_major_he.html

Image result for UPMC

 

Health care giant University of Pittsburgh Medical Center plans to spend $235 million in the Harrisburg, York and Lancaster areas in 2018. Much of it would go toward a new hospital in York, with some also spent at three other midstate hospitals.

Another $235 million could “potentially” go toward refinancing the loan Harrisburg-based PinnacleHealth System used for its recent purchase of four hospitals. UPMC and PinnacleHealth are in the process of merging, although the transaction still needs government approval.

The building plans were revealed Thursday during a public hearing on raplidly-expanding UPMC’s application for a bond issue through the Pennsylvania Economic Development Financing Authority. UPMC expects to receive $750 million from the bonds,

About $350 million would be used to pay off prior debt and about $400 would go toward new building projects and renovations. All told, UPMC plans to spend $900,000 million on building projects and related upgrades in western and central Pennsylvania in 2018, according to UPMC’s Simon Goehring, who represented UPMC at Thursday’s hearing.

UPMC now covers more than half the state — much more than any other system.

While PEDFA serves as a conduit for selling the bonds, there is no taxpayer funding involved in the bond issue or the funds UPMC would receive, PEDFA Executive Director Steve Drizos said. Going through PEDFA will enable UPMC to sell bonds that are exempt from state and federal interest taxes, resulting in lower costs for bond buyers, and lower financing costs for UPMC.

At Thursday’s legally-required public hearing, Dan Dorsheimer of AIA Benefits Resource Group asked whether UPMC plans to stops accepting any health insurance plans at the central Pennsylvania health care facilities that will come under its umbrella as a result of the PinnacleHealth merger.

Goehring replied that UPMC has no short-term plans to shut out any insurers, but “I can’t say in the long run how things will turn out.” UPMC is unusual among health systems in that it also owns a health insurance company.

In the Pittsburgh region, a dispute between UPMC and health insurer Highmark resulted in UPMC no longer accepting Highmark coverage.

Dorsheimer, whose firm manages employer health benefits and also is an insurance broker, said it’s “disruptive” and detrimental to health care consumers when any local health care providers won’t accept their health insurance.

“You witnessed what went on in Pittsburgh. It’s been very disruptive,” he said following the hearing.

The $235 million that will be spent in the midstate will be concentrated at facilities including Carlisle Regional Medical Center, York Memorial Hospital, which is being replaced, Lancaster Regional Medical Center, and Heart of Lancaster Regional Medical Center. Those are the four recently acquired by PinnacleHealth for $231 million.

PinnacleHealth is one of the region’s largest health care providers

Goehring also said UPMC also plans to spend some of the bond funds on a new hospital in the Pittsburgh area. Some also will be spent in north central Pennsylvania, where UPMC has acquired or plans to acquire several hospitals including the former Susquehanna Health.

A PEDFA committee has already approved the UPMC bond application. Final approval comes from Gov. Tom Wolf. Historically, the governor has typically approved applications that have been approved by the executive board, Drizos said.

Independence Is Not a Strategy for Health Systems

http://www.healthleadersmedia.com/leadership/independence-not-strategy-health-systems?spMailingID=11725844&spUserID=MTY3ODg4NTg1MzQ4S0&spJobID=1221639238&spReportId=MTIyMTYzOTIzOAS2#

Image result for john gribbin centrastate

There are ways to keep going it alone in the face of massive consolidation, says one health system’s CEO. It’s not a strategy, but a means to end, he says.

Afraid your hospital or health system can’t compete because you lack size and scale?

A merger might help, but it’s not the only possible answer to your problems. Freehold, NJ-based CentraState Healthcare System’s top leader is certain it’s not the best solution for his organization.

Consolidation continues to upend the acute and post-acute healthcare industry. In fact, in a recent HealthLeaders Media survey, some 87% of respondents said that their organization is exploring potential deals, completing deals already under way, or both.

But CentraState isn’t among them, says John Gribbin, its president and CEO.

On a continuum basis, CentraState is already diversified. That’s one of the potential selling points of an M&A deal.

Anchored by the 248-bed CentraState Medical Center in Freehold, NJ, the 2,300-employee organization also contains three senior care facilities—one assisted living, one skilled-nursing facility, and a continuing care retirement community.

It can be argued that CentraState may not possess the scale to compete with multifacility, multistate large health systems that can take advantage of a hub-and-spoke strategy for referrals. Nor may it be able to afford expensive interconnected IT systems.

But there ways other than mergers to achieve scale and collaboration, says Gribbin.

Means to an End

Gribbin insists that he and CentraState’s board, which supports and encourages independence, are not dogmatic about it.

“Independence is not a strategy,” he says. “It’s a means to an end. The moment that ceases to be worthwhile is the moment we’ll consider another way to achieve our mission.”

Change is part of that strategy, he says, adding that healthcare in 2017 needs to be far more collaborative, not only with patients and family, but with other healthcare organizations. That’s a big difference from previous generations.

“Our real strategy is scale and relevancy,” he says.

And there are ways to create scale short of taking on all the legacy costs and “baggage,” as Gribbin calls it, inherent in any merger.

“There’s a lot of costs involved in merging… and while mergers work in some instances, they don’t work in all, and in many communities, they are increasing costs to the consumer,” he says.

In addition to the commonly stated goals of improving the community’s health and wellness, patient costs are extremely important in fulfilling CentraState’s mission, Gribbin argues.

Many mergers involve replacing hospitals and adding patient towers and high-cost equipment. That adds to their cost structure means they have to extract higher pricing, says Gribben.

“That’s the vicious circle you find yourself in. I prefer to create scale in a different manner.”

Focus on the Mission

Gribbin, who has led CentraState for 17 years, prefers to solve that challenge in part through a strong network of physicians unburdened by excessive administrative overhead.

He says the health system has to increasingly take on value-based contracting and financial risk. To be successful under such value-based reimbursement, partnerships with physicians are increasingly important, as is a redefinition of the relationship with the patient.

“We used to look at our relationship with the patient as a typical hospital stay,” says Gribbin. “What we’re preaching now is that hospital stay is a temporary interruption in our relationship. What happens before or after defines the relationship’s success.”

With its physician alliance and clinically integrated network in place, CentraState, unlike many hospitals, has been able to avoid, in large part, expensive physician practice acquisitions that can be a financial challenge.

“I’ve done it in the past, and may do it again, but we’ve tried to avoid it,” he says. Instead, contracts define the relationships and incentives.

As an example of those relationships, CentraState partners with a major patient-centered medical home primary care practice on four performance and three utilization measures.

As a result of the shared savings generated in the first year, which came largely from hospital-based savings, the physicians in that group referred 59% of their patients to CentraState.

This year they’ve referred 71% of their patients to CentraState because of its low costs, which help drive financial reward for both parties under the contract.

“On one hand, we’re keeping people appropriately out of acute care, but on the other hand, they’re sending [more] people here. So we’re experiencing higher but more appropriate volume. In this scenario, everyone wins,” Gribbin says.

A New Deal with Physicians

In order to avoid the need to acquire physician practices, Gribbin says it helps to have a suite of services to offer them as a starting point.

“Most don’t want to sell their practice, but they feel like they have to, he says. “If you give them the opportunity to stay independent, they’ll take it.”

Helping them with access to better revenue cycle management, malpractice insurance, and risk management, and helping them create the ability to enter into risk-based contracts is another big help with defining a new relationship based on shared goals with physicians that ultimately benefit the patient, he says.

Physicians can establish a relationship with CentraState through its independent practice association, or a physician hospital association, and avoid surrendering their autonomy, he says.

“The physicians got paid better, the payer saved money even including the bonus, the hospital won because it’s high value care, and the patient’s winning too,” he says. “It’s a microcosm of what we’re trying to accomplish.”

As a small organization, both Gribbin and the board worry about being frozen out of narrow networks. Much of the energy they’ve expended in being a low-cost organization is wasted, he says, if they can’t get the big payers to include them in contracting.

“As long as the market isn’t rigged against us, we’re OK, because we’re a high-value organization.”

Dr. Soon-Shiong’s NantHealth to cut 300 jobs as losses mount

http://www.beckershospitalreview.com/hospital-management-administration/dr-soon-shiong-s-nanthealth-to-cut-300-jobs-as-losses-mount.html

Image result for nanthealth

NantHealth, a personalized medicine company led by billionaire Patrick Soon-Shiong, MD, will slash its workforce by 300.

The workforce reduction will occur through layoffs and transferring some staff to Allscripts Healthcare Solutions, according to NantHealth’s second quarter earnings release. Allscripts enteredinto an agreement Aug. 3 to buy NantHealth’s provider and patient engagement solutions business.

NantHealth said the workforce cutback and other steps taken by the company will result in $70 million in annualized cost savings.

NantHealth ended the first six months of 2017 with a net loss of $111.2 million, compared to a net loss of $87.3 million in the first half of 2016.

KeyBanc Capital Markets to acquire Cain Brothers

http://www.beckershospitalreview.com/hospital-transactions-and-valuation/keybanc-capital-markets-to-acquire-cain-brothers.html

Image result for key banc

 

Cleveland-based KeyBanc Capital Markets has entered into a definitive agreement to acquire New York City-based Cain Brothers & Co., a healthcare focused investment banking and public finance firm.

The transaction, which requires regulatory approvals, will expand KeyBanc’s healthcare investment banking group.

“Key’s established, integrated corporate and investment banking platform will allow us to bring enhanced capabilities to our clients, further improving our value proposition,” Robert J. Fraiman Jr., president and CEO of Cain Brothers, said. “At the same time, we look forward to bringing our knowledge and capabilities to Key’s extensive healthcare services and provider client base.”

The transaction is expected to close in late 2017.